Volume 1, Issue 8


Cover Image

Cover Figure: In silico PyMOL modeling showing a representation of the normal nonactivated αIIb (purple) and β3 (green) transmembrane and cytoplasmic tail segments, highlighting amino acids engaged in the inner membrane association clasp.
See the article by Nurden et al.

Join the discussion @ Blood Advances Community Conversations

WASHINGTON, March 14,  2017 – Welcome to the “Advance Notice,”  newsletter which provides highlights from issues of Blood Advances, the open-access journal of the American Society of Hematology (ASH), that  are hand-picked by Blood Advances Editor-in-Chief Robert Negrin, MD.

Treatment of complex diseases like leukemia is challenging, especially in resource-limited regions of the world. Through the work of the International Members Committee of the American Society of Hematology, efforts have been made to develop strategies to treat patients with acute promyelocytic leukemia in the developing world. Rego presents a Blood Advances Talk detailing the work of this important effort. This approach could serve as a model for many other areas of the world that need our urgent attention.

The use of techniques to identify patients with minimal residual disease (MRD) have been developed to monitor several different hematological malignancies and are now being incorporated into many treatment algorithms. In the Point-Counterpoint, Dr Anderson and Dr Sonneveld discuss the use of MRD assays as an endpoint for studies in multiple myeloma. Is this ready for primetime?

Intravenous immunoglobulin (IVIg) has been used in a variety of clinical conditions, including autoimmune disorders, due to its ability to modulate immune reactions in part related to aberrant activation of the complement cascade. However, IVIg is in limited supply and has a high cost. To overcome these challenges, a drug candidate called GL-2045 has been developed. The murine counterpart has been associated with control of a number of autoimmune diseases in animal models. In the report by Zhou et al, fully recombinant GL-2045 was found to inhibit complement-mediated toxicity and resulted in the generation of iC3b, setting the stage for clinical translation.

Featured Visual Abstract

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b

Hua Zhou, Henrik Olsen, Edward So, Emmanuel Mérigeon, Denis Rybin, Jane Owens, Gregory LaRosa, David S. Block, Scott E. Strome, Xiaoyu Zhang





Blood Advances is the official open-access journal of the American Society of Hematology (ASH) (, the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.